Medical costs associated with non-Hodgkin's lymphoma in the United States during the first two years of treatment

References

• Parkin D M, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74–108
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Cancer facts and figures 2005. American Cancer Society. 2005, Available from: http://www.cancer.org
   Google Scholar
• Brown M L, Riley G F, Schussler N, Etzioni R. Estimating health care costs related to cancer treatment from SEER-Medicare data. Medical Care 2002; 40(suppl. 8)IV-104–IV-117
   Web of Science ®Google Scholar
• Fireman B H, Quesenberry C P, Somkin C P, Jacobson A S, Baer D, West D, Potosky A L, Brown M L. Cost of care for cancer in a health maintenance organization. Health Care Financing Rev 1997; 18: 51–76
   PubMed Web of Science ®Google Scholar
• Barnett A, Birnbaum H, Cremieux P Y, Fendrick A M, Slavin M. The costs of cancer to a major employer in the United States: A case-control analysis. Am J Manag Care 2000; 6: 1243–1251
   PubMed Web of Science ®Google Scholar
• Zelenetz A, Tang B, Frame D, Nalysnyk L, Celia C, Noel J K. Clinical outcomes and cost of outpatient community-based treatment for rituximab refractory non-Hodgkin's lymphoma patients. Blood 2004; 104, [abstract 3132]
   PubMed Web of Science ®Google Scholar
• Menat C, Milpied N, Deconinck E, Colombat P, Ifrah N, Gressin R, Limat S, Delwail V, Monnet E, Woronoff-Lemsi M -C. Cost-effectiveness of high dose chemotherapy followed by autologous stem cell transplantation versus standard CHOP therapy for NHL patients in front-line therapy. Proc Am Soc Clin Oncol 2003; 22: 574, [abstract]
   Web of Science ®Google Scholar
• Shustik C, Laplante S, Meyer R. Cost comparison and cost efficacy analysis between fludarabine and cyclophosphamide, vincristine and prednisone treatments for indolent non-Hodgkin's lymphoma. Proc Am Soc Clin Oncol 2002; 21, [abstract 1126]
   Google Scholar
• Wirt D P, Giles F J, Oken M M, Solal-Celigny P, Beck R. Cost-effectiveness of interferon alfa-2b added to chemotherapy for high-tumor burden follicular non-Hodgkin's lymphoma. Leuk Lymphoma 2001; 40: 565–579
   PubMed Web of Science ®Google Scholar
• Schulman K A, Dorsainvil D, Yabroff K R, DiCesare J, Felser J, Eisenberg J M, Glick H A. Prospective economic evaluation accompanying a trial of GM-CSF/IL-3 in patients undergoing autologous bone marrow transplantation for Hodgkin's and non-Hodgkin's lymphoma. Bone Marrow Transplant 1998; 21: 607–614
   PubMed Web of Science ®Google Scholar
• Chang S, Long S R, Kutikova L, Bowman L, Finley D, Crown W H, Bennett C L. Estimating the cost of cancer: results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000. J Clin Oncol 2004; 22: 3524–3530
   PubMed Web of Science ®Google Scholar
• Barnes C A. Disease staging: A clinically oriented dimension of case mix. Am Med Record Assoc 1985; 56: 22–27
   PubMedGoogle Scholar
• Duan N. Smearing estimate: A nonparametric retransformation method. JASA 1983; 78: 605–610
   Web of Science ®Google Scholar
• Brown M L, Lipscomb J, Snyder C. The burden of illness of cancer: economic cost and quality of life. Annu Rev Public Health 2001; 22: 91–113
   PubMed Web of Science ®Google Scholar
• Burkhardt J H, Sunshine J H. Core-needle and surgical breast biopsy: comparison of three methods of assessing cost. Radiology 1999; 212: 181–188
   PubMed Web of Science ®Google Scholar
• Warren J L, Brown M L, Fay M P, Schussler N, Potosky A L, Riley G F. Cost of treatment for elderly women with early-stage breast cancer in fee-for-service settings. J Clin Oncol 2002; 20: 307–316
   PubMed Web of Science ®Google Scholar
• Kuruvilla J, Cavalcanti R, Keating A, Crump M. Addition of rituximab to CHOP is an attractive strategy as primary therapy for diffuse large B-cell lymphoma in patients age <60 years: An economic analysis. Blood 2004; 104, [abstract 3126]
   Web of Science ®Google Scholar
• Coiffier B, Best J H, Omnes L F, Hornberger J C. Cost-effectiveness of rituximab in treatment of diffuse large B-cell lymphoma. Blood 2001; 98, [abstract 3586]
   Google Scholar
• Hieke K, Pasold R, Neser S, Niederwieser D, Neubauer A, Doelken G, Naumann R, Fietz T, Freund M, Rohrberg R, et al. Cost evaluation of rituximab plus MCP vs. MCP alone in advanced stage indolent non-Hodgkin's lymphoma based on a randomized controlled multicenter trial. Blood 2004; 104, [abstract 87]
   Web of Science ®Google Scholar
• Vellenga E, van Agthoven M, Croockewit A J, Verdonck L F, Wijerman P J, van Oers M HJ, Volkers C P, van Imhoff G W, Kingma T, Uyl-de Groot C A, et al. Autologous peripheral blood stem cell transplantation in patients with relapse lymphoma results in accelerated haematopoietic reconstitution, improved quality of life and cost reduction compared with bone marrow transplantation: the Hovon 22 study. Br J Haematol 2001; 114: 319–326
   PubMed Web of Science ®Google Scholar
• Cabanillas F, Velasquez W S, Hagemeister F B, McLaughlin P, Redman J R. Clinical, biologic, and histologic features of late relapses in diffuse large cell lymphoma. Blood 1992; 79: 1024–1028
   PubMed Web of Science ®Google Scholar